松龄血脉康胶囊联合非诺贝特在糖尿病合并血脂代谢异常治疗中的临床研究

目的 探讨松龄血脉康胶囊联合非诺贝特胶囊治疗糖尿病合血脂代谢异常的临床疗效。方法 选取2016年7月—2018年7月在南平市第一医院就诊的260例糖尿病合血脂代谢异常患者，随机分为观察组（n=130）和对照组（n=130）。对照组患者口服非诺贝特胶囊，200 mg/次，1次/d。观察组在对照组基础上给予松龄血脉康胶囊，3粒/次，3次/d。4周为1个疗程，两组患者均治疗2个疗程。观察两组患者的临床疗效，比较两组的糖代谢指标、血脂代谢指标及不良反应发生情况。结果 治疗后，与对照组总有效率（80.00%）比较，观察组总有效率（93.85%）显著升高（P<0.05）。治疗后，两组空腹血糖（FBG）、餐后2 h血糖（2 hPG）、糖化血红蛋白（HbA1c）和胰岛素抵抗指数（HOMA-IR）水平均显著低于治疗前（P<0.05），且观察组糖代谢指标显著低于对照组（P<0.05）。治疗后，两组总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白（HDL-C）和低密度脂蛋白（LDL-C）水平与治疗前比较均显著改善（P<0.05），且观察组血脂代谢指标显著优于对照组（P<0.05）。两组不良反应发生率比较差异无统计学意义。结论 松龄血脉康胶囊联合非诺贝特胶囊可有效改善糖尿病合血脂代谢异常患者的血糖和血脂水平，值得临床推广。

Clinical study of Songling Xuemaikang Capsules combined with fenofibrate in treatment of diabetes mellitus with dyslipidemia

Objective To investigate the clinical effect of Songling Xuemaikang Capsules combined with Fenofibrate Capsules in treatment of diabetes mellitus with dyslipidemia. Methods Patients (260 cases) with diabetes mellitus and dyslipidemia in The Nanping First Hospital from July 2016 to July 2018 were randomly divided into observation group (n=130) and control group (n= 130). Patients in the control groups were po administered with Fenofibrate Capsules, 200 mg/time, once daily. Patients in the observation groups were treated with Songling Xuemaikang Capsules on the basis of control groups, 3 grains/time, three times daily. 4 weeks as one course, patients in two groups were treated for 2 courses. After treatment, the clinical effect in two groups was observed, and the glycometabolism indexes, blood lipid metabolism indexes, and adverse reactions between two groups were compared. Results After treatment, compared with the total effective rate in the control group (80.00%), the total effective rate in the observation group (93.85%) was significantly increased (P < 0.05). After treatment, the levels of FBG, 2 hPG, HbA1c, and HOMA-IR in two groups were significantly decreased (P < 0.05), and the glycometabolism indexes levels in the observation group was significantly lower than those in the control group (P < 0.05). After treatment, the levels of TC, TG, HDL-C, and LDL-C in two groups were significantly improved (P < 0.05), and the blood lipid metabolism indexes in the observation group was significantly better than those in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion Songling Xuemaikang Capsules combined with Fenofibrate Capsules can effectively improve blood gluose and lipid levels in patients with diabetes mellitus with dyslipidemia, which is worthy of clinical promotion.